Skip to content
Life Sciences Series B Founded 2015

Rhelixa

Provider of integrated genomic analysis platform. The company uses its core algorithm as a core technology for analyzing exhaustive epigenome data obtained from the next-generation sequencer. The company also provides next-generation sequencing data analysis services. Founded in 2015, headquartered in Chiyoda City, Japan. The company has raised $5.6M in funding at the series b stage. The team comprises 8 (Jun 30,…

📍 Chiyoda City, Japan · Genomics,

Funding snapshot

Last roundSeries B
Amount$3M
Date20 August 2024
Total raised$6M
Team size8

About

Provider of integrated genomic analysis platform. The company uses its core algorithm as a core technology for analyzing exhaustive epigenome data obtained from the next-generation sequencer. The company also provides next-generation sequencing data analysis services. Founded in 2015, headquartered in Chiyoda City, Japan. The company has raised $5.6M in funding at the series b stage. The team comprises 8 (Jun 30, 2026) employees. The company operates in the Genomics sector with additional focus on Life Sciences Tech and Life Sciences Tech. Its business model centers on Omics Analysis. Founded in 2015, headquartered in Chiyoda City, Japan. The company has raised $5.6M at the Series B stage. Backed by investors including Leave a Nest Capital, JFC, Joyo Bank, Daiwa Corporate Investment, Kirin and others.

Business model

Life Sciences Tech > Research & Development > Drug Informatics > Clinical Data Analysis > Omics Analysis,

Genomics > Genome Informatics > Integrative Bioinformatics Platforms

Institutional investors

Leave a Nest Capital JFC Joyo Bank Daiwa Corporate Investment Kirin Mitsubishi Corporation Sompo Leave a Nest

Latest coverage

No articles yet.

Raising like Rhelixa?

Analyze your pitch deck before your next raise.

Analyze My Deck →